Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q4 2025 Earnings Presentation
9 slides from Sanuwave Health's earnings presentation, Mar 27, 2026
Slide 1: Q4 and Full Year 2025
Q4 and Full Year 2025 March 26, 2026
Slide 2: Live Presentation and Dial-in Information
Live Presentation Friday, March 27, 2026, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-343-4136 Toll/International: 1-203-518-9843 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1753775&tp_key=6ca0a4c
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q4 2025
4 Financials Q4 2025 Consistent topline growth while managing operating costs. (in millions) Q4 2025 Q4 2024 YoY Revenue $13.4 $10.3 + 30% Gross Profit $10.0* $8.0 + 24% Gross Margin % 74.7%* 77.9% -320 bp Operating Expense $8.0** $6.0 +33% Revenue Gross Profit Operating Income Operating Income $2.0
Slide 5: Adjusted Gross Margin and Adjusted Operating Income
5 Adjusted Gross Margin and Adjusted Operating Income (in millions) Q4 2025 Q4 2024 YoY Gross Margin % 74.7% 77.9% -320 bp Inventory write-off $0.5 - Adjusted Gross Margin % 78.3% 77.9% +40 bp Adjusted Gross Margin Operating Income $2.0 $2.0 0% Inventory write-off $0.5 - Sales Tax Expense $0.5 $0.5
Slide 6: Improved Operational Results
6 Improved Operational Results See Non-GAAP Financial Measures disclosure included on slide 3 1 The charges represent an isolated state and local sales tax expense related to the restatement of prior period financial statements. 2 The charges represent the net amount of proceeds received of $0.4 mil
Slide 7: Growing UltraMIST Systems & Consumables Sales
7 Growing UltraMIST Systems & Consumables Sales Growth in UltraMIST Systems and Applicators year on year. Record quarter for systems sold. $8.0 *Please note: In Q4 2025, we transitioned to tracking Q4 2025: “active systems”, which are defined as those owned by customers who have ordered consumable a
Slide 8: Q1 and FY 2026 Revenue Guidance
8 Q1 and FY 2026 Revenue Guidance Q1 2026 FY 2026 REVENUE TARGET REVENUE TARGET $9.6-10.3 Million $51.0-55.0 million (+3-10%) (+16-25%) vs vs Q1 2025 REVENUE FY 2025 REVENUE of $9.3 million of $44.1 million
Slide 9: Summary
9 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved product protected by strong IP ▪ Strong existing reimbursement with room to impro